Search

Your search keyword '"Welch, Stephen"' showing total 1,272 results

Search Constraints

Start Over You searched for: Author "Welch, Stephen" Remove constraint Author: "Welch, Stephen"
1,272 results on '"Welch, Stephen"'

Search Results

206. Virucidal Efficacy of Guanidine-Free Inactivants and Rapid Test Buffers Against SARS-CoV-2: Implications for Risk Assessment of Diagnostic Procedures

209. ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (1307)

210. Testing for knowledge: Application of machine learning techniques for prediction of flashover in a 1/5 scale ISO 13784‐1 enclosure

211. Sustained replication of synthetic canine distemper virus defective genomes in vitro and in vivo

225. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019

226. Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.

227. Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

228. Patient self-reporting of tolerability using PRO-CTCAE: A randomized double-blind placebo controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in women with platinum resistant epithelial ovarian cancer.

229. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

231. Precise multispecies agricultural gas flux determined using broadband open-path dual-comb spectroscopy

234. Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial

235. Contributor contact details

241. Still in the mix: the cupboard may be bare, but creative communicators are devising their own recipes

244. Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events

245. Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

247. Feedlot-produced ammonia emissions quantified using dual-comb spectroscopy

248. A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

249. Broadband dual-comb spectroscopy for open-path field measurement of H216O and H218O

250. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Catalog

Books, media, physical & digital resources